# A Study of CT-868 in Type 1 Diabetes Mellitus

> **NCT06062069** · PHASE2 · COMPLETED · sponsor: **Carmot Therapeutics, Inc.** · enrollment: 111 (actual)

## Conditions studied

- Overweight
- Obese
- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** CT-868
- **DEVICE:** CT-868 Pen Injector
- **DRUG:** CT-868 Pen Injector, Placebo

## Key facts

- **NCT ID:** NCT06062069
- **Lead sponsor:** Carmot Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-19
- **Primary completion:** 2025-07-09
- **Final completion:** 2025-07-09
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06062069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06062069, "A Study of CT-868 in Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06062069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*